title: Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease.
abstract: To evaluate the effects of bromocriptine on bladder function in Parkinson's disease (PD) patients and compare these effects with those of (L-dopa). We recruited 8 patients with PD. Urodynamic study (UDS) was performed before and 1 hour after administering 100 mg L-dopa/decarboxylase inhibitor (DCI) and 2.5 hours after administering 7.5 mg bromocriptine. After the bromocriptine administration, urinary urgency aggravated. UDS revealed a decreased bladder volume at which detrusor overactivity (DO) was initiated, a decreased bladder volume at first sensation of bladder filling (FSV) (P < 0.05), an increased maximum Watts Factor value (WFmax) (detrusor contractility), a decreased Abrams-Griffiths (AG) number (urethral obstruction), and a decreased postvoid residual (PVR) (P < 0.01). Similarly, after the L-dopa administration, urinary urgency aggravated. UDS revealed an aggravated DO (P < 0.05), a decreased FSV and bladder capacity (P < 0.01, 0.05), an increased WFmax (P < 0.05), an increased AG number, and a decreased PVR (P < 0.01). A single dose of bromocriptine proved to exacerbate urinary urgency and DO in the storage phase, and improve bladder emptying through increased detrusor contractility and decreased bladder outlet obstruction, within hours. With the exception of bladder outlet obstruction, these effects of bromocriptine are similar to the effects of L-dopa, albeit slightly less pronounced.
authors.affiliation: Department of Neurology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan. uchiyama@faculty.chiba-u.jp
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Ryuji
authors.initials: R
authors.lastname: Sakakibara
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Ito
authors.forename: Chiharu
authors.initials: C
authors.lastname: Yamaguchi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Awa
authors.forename: Masashi
authors.initials: M
authors.lastname: Yano
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Yanagisawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Higuchi
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Ichikawa
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yamanishi
authors.forename: Takamichi
authors.initials: T
authors.lastname: Hattori
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kuwabara
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D010300:Parkinson Disease / Q000150:complications*; D011446:Prospective Studies; D012212:Rheology / Q000379:methods; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000209:etiology*; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000978:Antiparkinson Agents; D001971:Bromocriptine; D007980:Levodopa